targeted delivery of small interfering rna using reconstituted high-density lipoprotein nanoparticles

Clicks: 186
ID: 194598
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #109 of 203 articles by views in ACS chemical neuroscience

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 203 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular characteristic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into reconstituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches.
Reference Key
shahzad2011neoplasia:targeted Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Mian M.K. Shahzad;Lingegowda S. Mangala;Hee Dong Han;Chunhua Lu;Justin Bottsford-Miller;Masato Nishimura;Edna M. Mora;Jeong-Won Lee;Rebecca L. Stone;Chad V. Pecot;Duangmani Thanapprapasr;Ju-Won Roh;Puja Gaur;Maya P. Nair;Yun-Yong Park;Nirupama Sabnis;Michael T. Deavers;Ju-Seog Lee;Lee M. Ellis;Gabriel Lopez-Berestein;Walter J. McConathy;Laszlo Prokai;Andras G. Lacko;Anil K. Sood
Journal ACS chemical neuroscience
Year 2011
DOI
10.1593/neo.101372
URL
http://www.sciencedirect.com/science/article/pii/S1476558611800126
Keywords
neoplasms Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.